UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000024438 |
|---|---|
| Receipt number | R000028092 |
| Scientific Title | A Phase II, Open Label, Randomized Study of Osimertinib (TAgrisso) alone Versus Osimertinib plus Carboplatin/Pemetrexed for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose TUmours Harbour a T790M MutatIon Within the Epidermal Growth Factor Receptor Gene |
| Date of disclosure of the study information | 2016/10/17 |
| Last modified on | 2020/04/20 18:16:27 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2016/10/17 13:25:39 | ||
| 2 | Update | 2016/10/19 10:23:38 | UMIN ID1 |
|
| 3 | Update | 2016/10/19 10:35:31 | UMIN ID2 |
|
| 4 | Update | 2016/11/28 11:09:53 | Recruitment status Anticipated trial start date |
|
| 5 | Update | 2017/10/17 11:38:03 | Key inclusion criteria Key inclusion criteria |
|
| 6 | Update | 2020/04/20 18:16:27 | Recruitment status Date of IRB Last follow-up date |
